Novartis division Sandoz has partnered with Chinese manufacturer Gan & Lee to bring biosimilar insulins to the US and EU. The agreement will see China’s Gan & Lee supply Sandoz with insulin glargine, lispro and aspart products for use in patients with type 1 and type 2 diabetes for commercialization in Europe and the US, along with other key markets. “After conducting a significant review, Sandoz decided to collaborate with Gan & Lee, the third largest insulin distributor headquartered in…